LianBio Q2 net loss $42.4M; cash $349.4M; mavacamten China Phase 3 enrollment complete

LianBio

2022-Q2 EPS reported -$0.65

Net loss of $42.4M in Q2 2022 vs. $100.4M loss in Q2 2021; R&D expenses fell to $28.6M.
Cash balance $349.4M at June 30, 2022; runway projected into second half of 2024.
Completed enrollment in China Phase 3 EXPLORER-CN trial of mavacamten; topline data mid-2023.
Submitted NDAs: mavacamten in Singapore (oHCM) and infigratinib in Hong Kong (cholangiocarcinoma).
Three additional registration-enabling programs (TP-03, NBTXR3, BBP-398) to begin in China by year-end 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.